These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 3859935)

  • 1. Evolution of clinical studies with high-dose cytosine arabinoside at the M.D. Anderson Hospital.
    Keating MJ; Estey E; Plunkett W; Iacoboni S; Walters R; Kantarjian H; Andersson B; Beran M; McCredie KB; Freireich EJ
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):98-104. PubMed ID: 3859935
    [No Abstract]   [Full Text] [Related]  

  • 2. Modulation of cytosine arabinoside (ara-C) and high-dose ara-C in acute leukemia.
    Zittoun R; Marie JP; Zittoun J; Marquet J; Haanen C
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):139-43. PubMed ID: 3859928
    [No Abstract]   [Full Text] [Related]  

  • 3. Cellular pharmacology and optimal therapeutic concentrations of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in leukemic blasts during treatment of refractory leukemia with high-dose 1-beta-D-arabinofuranosylcytosine.
    Plunkett W; Iacoboni S; Keating MJ
    Scand J Haematol Suppl; 1986; 44():51-9. PubMed ID: 3457439
    [No Abstract]   [Full Text] [Related]  

  • 4. Sequential high-dose ara-C and asparaginase in the therapy of previously treated and untreated patients with acute leukemia.
    Capizzi RL; Powell BL; Cooper MR; Stuart JJ; Muss HB; Richards F; Jackson DV; White DR; Spurr CL; Zekan PJ
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):105-13. PubMed ID: 3892697
    [No Abstract]   [Full Text] [Related]  

  • 5. Studies on the cytotoxicity of cytosine arabinoside.
    Haanen C; Muus P; Raymakers R; Drenthe-Schonk A; Salden M; Wessels J
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):120-9. PubMed ID: 3892698
    [No Abstract]   [Full Text] [Related]  

  • 6. Central nervous system toxicity with high-dose cytosine arabinoside.
    Herzig RH; Lazarus HM; Herzig GP; Coccia PF; Wolff SN
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):233-6. PubMed ID: 3892703
    [No Abstract]   [Full Text] [Related]  

  • 7. Rationales for a pharmacologically optimized treatment of acute nonlymphocytic leukemia with cytosine arabinoside.
    Heinemann V; Jehn U
    Leukemia; 1990 Nov; 4(11):790-6. PubMed ID: 2232893
    [No Abstract]   [Full Text] [Related]  

  • 8. [Cytosine-arabinoside in the treatment of acute leukemias].
    Böhnel J; Gingold N; Hermansky F; Pawlowski M; Stacher A
    Wien Med Wochenschr; 1972 Apr; 122(15):203-7. PubMed ID: 4527321
    [No Abstract]   [Full Text] [Related]  

  • 9. Experience with the use of cytosine arabinoside in adult acute leukaemia.
    Brodie GN; Penny R
    Med J Aust; 1970 Mar; 1(13):635-7. PubMed ID: 5267173
    [No Abstract]   [Full Text] [Related]  

  • 10. Central nervous system toxicity of high-dose cytosine arabinoside.
    Barnett MJ; Richards MA; Ganesan TS; Waxman JH; Smith BF; Butler MG; Rohatiner AZ; Slevin ML; Lister TA
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):227-32. PubMed ID: 3925559
    [No Abstract]   [Full Text] [Related]  

  • 11. Preliminary evaluation of cyclophosphamide (NSC-26271) and cytosine arabinoside (NSC-63878) in acute leukemia of children.
    Freedman MH; Finklestein JZ; Gilchrist GS; Hammond GD; Higgins GR; Hyman CB; Shore NA; Williams KO; Karon MR
    Cancer Chemother Rep; 1969 Oct; 53(5):299-303. PubMed ID: 5270583
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacokinetics and cellular determinants of response to 1-beta-arabinofuranosylcytosine (ara-C).
    Riva CM; Rustum YM; Preisler HD
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):1-8. PubMed ID: 3859925
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical use of cytosine arabinoside in infancy. I. Cytosine arabinoside in the treatment of acute leukosis].
    Masi M; Vivarelli F; Paolucci P; Vecchi V
    Minerva Pediatr; 1975 Sep; 27(28):1539-50. PubMed ID: 1101022
    [No Abstract]   [Full Text] [Related]  

  • 14. High-dose cytosine arabinoside in the treatment of resistant acute leukemia.
    Takaku F; Urabe A; Mizoguchi H; Yamada O; Wakabayashi Y; Miura Y; Sakamoto S; Yoshida M; Miwa S; Asano S
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):144-9. PubMed ID: 3859929
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacologically directed design of leukemia therapy.
    Plunkett W; Heinemann V; Estey E; Keating M
    Haematol Blood Transfus; 1990; 33():610-3. PubMed ID: 2182451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daunorubicin (NSC-82151), vincristine (NSC-67574), cytosine arabinoside (NSC-63878), and prednisone (NSC-10023) combination therapy for advanced adult acute leukemia.
    Burns CP
    Cancer Chemother Rep; 1975; 59(4):757-60. PubMed ID: 1100227
    [No Abstract]   [Full Text] [Related]  

  • 17. [Experiences in the treatment of immature cell leukemias with cytosine arabinoside and daunorubidomycin].
    Schmalzl F; Braunsteiner H
    Wien Klin Wochenschr; 1971 Jun; 83(25):452-6. PubMed ID: 5289111
    [No Abstract]   [Full Text] [Related]  

  • 18. High-dose cytosine arabinoside in the initial treatment of acute leukemia.
    Barnett MJ; Waxman JH; Richards MA; Ganesan TS; Bragman KS; Rohatiner AZ; Lister TA
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):133-8. PubMed ID: 3859927
    [No Abstract]   [Full Text] [Related]  

  • 19. Cytosine arabinoside and herpes zoster.
    Mann JR
    Lancet; 1971 Jul; 2(7716):166. PubMed ID: 4104494
    [No Abstract]   [Full Text] [Related]  

  • 20. [High doses of cytosine arabinoside in the treatment of refractory leukemia].
    Klener P; Háber J; Kolesková E
    Sb Lek; 1987 Sep; 89(8-9):271-5. PubMed ID: 3478794
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.